SLC5A2 and Hypoglycemia: Another recent meta‐analysis demonstrated that combination therapy with SGLT2‐Is and ACEIs/ARBs compared with ACEIs/ARBs was well‐tolerated and achieved better control of blood pressure, improvement of renal outcomes, alleviation of long‐term renal function and a decrease in blood glucose and body weight, but an increased risk of hypoglycaemia.22